Related Experiment Video
Updated: Jun 20, 2026
Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
Published on: May 2, 2011
The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and
Seung-Phil Shin1, Kwang-Soo Shin1, Jeong-Mi Lee1
1Cellid Co., Ltd., Seoul 08826, Korea.
A novel adenovirus-based COVID-19 vaccine, AdCLD-CoV19, demonstrated robust antigen expression and induced strong immune responses in mice and non-human primates after a single dose. This vaccine effectively protected non-human primates against live SARS-CoV-2 and showed adaptability against variants with booster shots.
Area of Science:
- * Virology and Immunology
- * Vaccine Development and Delivery Systems
Background:
- * Existing COVID-19 vaccine platforms require ongoing research for optimal antigen delivery and broad efficacy.
- * Development of effective vaccine platforms is crucial for controlling the SARS-CoV-2 pandemic.
Purpose of the Study:
- * To construct and evaluate AdCLD-CoV19, an adenovirus-based vaccine platform designed to enhance humoral and cellular immunity against SARS-CoV-2.
- * To assess the immunogenicity and protective efficacy of AdCLD-CoV19 in preclinical models.
Main Methods:
- * Construction of AdCLD-CoV19 by incorporating SARS-CoV-2 antigens onto a chimeric adenovirus 5/35 platform.
- * Modification of the SARS-CoV-2 Spike (S) protein by replacing the S1/S2 furin cleavage sequence with a linker sequence.
- * Evaluation of antigen expression, antibody activity, Th1 immune responses, and protection against live SARS-CoV-2 in mice and non-human primates (NHPs).
Main Results:
- * High SARS-CoV-2 antigen expression was confirmed in cell lines using the modified AdCLD-CoV19 platform.
- * A single vaccination of AdCLD-CoV19 induced significant antigen-specific antibody activity in mice and NHPs.
- * Adenovirus-induced Th1 immune responses targeting the S protein conferred protection in NHPs challenged with live SARS-CoV-2.
- * AdCLD-CoV19 maintained neutralizing antibody activity against SARS-CoV-2 variants, with efficacy restored by booster shots for reduced responses against beta and omicron variants.
Conclusions:
- * AdCLD-CoV19 is a promising vaccine candidate capable of inducing potent humoral and cellular immunity against SARS-CoV-2.
- * The platform demonstrated single-dose efficacy and adaptability against emerging variants through strategic vaccination approaches.
- * AdCLD-CoV19 offers a potential solution for preventing COVID-19 and managing evolving SARS-CoV-2 strains.
More Related Videos
13:36Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
10:39Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
